 Despite intensive preclinical research, no β-catenin inhibitors are available as therapeutic agents yet.However, its function can be further examined by siRNA knockdown based on an independent validation.Another therapeutic approach for reducing β-catenin nuclear accumulation is via the inhibition of galectin-3.